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Abstract
Background: Folate and its synthetic form folic acid function as donor of one-carbon units and have been,
together with other B-vitamins, implicated in programming of epigenetic processes such as DNA methylation
during early development. To what extent regulation of DNA methylation can be altered via B-vitamins later in life,
and how this relates to health and disease, is not exactly known. The aim of this study was to identify effects of
long-term supplementation with folic acid and vitamin B12 on genome-wide DNA methylation in elderly subjects.
This project was part of a randomized, placebo-controlled trial on effects of supplemental intake of folic acid and
vitamin B12 on bone fracture incidence (B-vitamins for the PRevention Of Osteoporotic Fractures (B-PROOF) study).
Participants with mildly elevated homocysteine levels, aged 65–75 years, were randomly assigned to take 400 μg
folic acid and 500 μg vitamin B12 per day or a placebo during an intervention period of 2 years. DNA was isolated
from buffy coats, collected before and after intervention, and genome-wide DNA methylation was determined in
87 participants (n = 44 folic acid/vitamin B12, n = 43 placebo) using the Infinium HumanMethylation450 BeadChip.
Results: After intervention with folic acid and vitamin B12, 162 (versus 14 in the placebo group) of the 431,312
positions were differentially methylated as compared to baseline. Comparisons of the DNA methylation changes in
the participants receiving folic acid and vitamin B12 versus placebo revealed one single differentially methylated
position (cg19380919) with a borderline statistical significance. However, based on the analyses of differentially
methylated regions (DMRs) consisting of multiple positions, we identified 6 regions that differed statistically
significantly between the intervention and placebo group. Pronounced changes were found for regions in the
DIRAS3, ARMC8, and NODAL genes, implicated in carcinogenesis and early embryonic development.
Furthermore, serum levels of folate and vitamin B12 or plasma homocysteine were related to DNA methylation of
173, 425, and 11 regions, respectively. Interestingly, for several members of the developmental HOX genes, DNA
methylation was related to serum levels of folate.
Conclusions: Long-term supplementation with folic acid and vitamin B12 in elderly subjects resulted in effects on
DNA methylation of several genes, among which genes implicated in developmental processes.
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Background
During early development, DNA methylation is one of
the epigenetic phenomena responsible for program-
ming of gene expression profiles [1]. It has been
shown that the plasticity of epigenetic regulation can
be determined by environmental factors, such as par-
ental diet and lifestyle, during the critical windows in
early development [1–3]. B-vitamins play an essential
role in one-carbon metabolism and have, as such, also
been implicated in the regulation of DNA methylation
and DNA synthesis [1, 4–6].
Recently, neonatal folate-sensitive regions of differen-
tial methylation were identified based on the maternal
folate status during the last trimester of pregnancy [7].
Maternal use of folic acid before and during pregnancy
has been previously associated with specific DNA
methylation patterns in the infants [8–10]. Also, mater-
nal vitamin B12 levels have been shown to influence
global DNA methylation in cord blood, whereas infants’
levels of vitamin B12 were associated with distinct
gene-specific DNA methylation patterns [11]. These
findings illustrate and confirm the potential role of B-
vitamins on DNA methylation during early develop-
ment [12, 13].
The “developmental origins of health and disease”
hypothesis states that adult diseases often originate
from aberrant epigenetic programming during early
development [14, 15]. To what extent environmental
exposures later in life can induce changes in DNA
methylation and how this relates to development of
adult diseases is an emerging field of research. Al-
though some studies demonstrate plasticity of DNA
methylation in adults [16, 17], it is still largely un-
known to what extent B-vitamins involved in one-
carbon metabolism can affect DNA methylation
throughout the life cycle. Although not consistently,
suboptimal levels of B-vitamins and homocysteine, a
major key player in one-carbon metabolism, in adult
life have been implicated in several clinical phenotypes
[18], such as an increased risk of osteoporosis [19, 20],
vascular diseases [21, 22], cognitive impairment [23], and
cancer [24–26]. There is a growing body of evidence that
the association between B-vitamins and disease risk im-
plies a narrow range of an optimal B-vitamin status, and
depends, in case of cancer, on the presence of preclinical
neoplastic lesions [27–30]. Detailed insight into the effects
of B-vitamins on DNA methylation is therefore urgently
required in order to elucidate the mechanisms underlying
the suggested effects of these B-vitamins on health and
disease in adult life.
The aim of the current study was to determine the ef-
fects of a long-term daily supplementation with folic
acid and vitamin B12 on genome-wide DNA methylation
in leukocytes of elderly subjects.
Results
Biochemical analyses
As shown in Fig. 1, 44 participants were randomized to
the intervention with folic acid and vitamin B12, while
43 participants were assigned to the placebo group.
Baseline characteristics of the participants are pre-
sented in Table 1. Inherent to the selection procedure
for our study, participants with the methylenetetrahy-
drofolate reductase (MTHFR) (C677T) CC and TT ge-
notypes were equally distributed among the groups.
Age, body mass index, and serum levels of folate, vita-
min B12, and plasma homocysteine at baseline did not
differ between the two groups. The 2-year intervention
with folic acid and vitamin B12 resulted in increased
serum levels of both B-vitamins (folate median change
34.0 nmol/L; vitamin B12 median change 319 pmol/L)
as well as decreased levels of homocysteine (median
change −5.3 μmol/L). The changes in these levels were sta-
tistically significantly different from the ones observed in
the placebo group (median change for folate 5.4 nmol/L,
vitamin B12 30.4 pmol/L, and homocysteine −1.5 μmol/L,
for all parameters p < 0.0001). Individual changes in levels
of serum folate, vitamin B12, and plasma homocysteine are
presented in Fig. 2.
Leukocyte proportions
In order to assess whether the mean leukocyte compos-
ition changed as a result of the intervention or duration
of the study, leukocyte proportions were estimated based
on DNA methylation data. The composition of the
leukocyte fraction was similar for participants receiving
folic acid and vitamin B12 or placebo and for both time
points (Additional file 1: Figure S1). The Pearson correl-
ation coefficient for estimated versus measured cell pro-
portions in all follow-up samples (n = 85, 2 missing
samples) was 0.66 for monocytes, 0.45 for lymphocytes
(CD4+ and CD8+ T-lymphocytes, natural killer cells, and
B-lymphocytes), and 0.46 for granulocytes (eosinophils,
basophils, and neutrophils). No significant differences in
measured or estimated cell proportions between the pla-
cebo and intervention group were measured at follow-up.
Differentially methylated positions
At baseline, there were no statistically significant differ-
ences in methylation between the placebo and the inter-
vention group. After intervention with folic acid and
vitamin B12, 162 positions (versus 14 in the placebo
group) of the 431,312 positions were differentially meth-
ylated as compared to baseline (Benjamini-Hochberg
(BH)-adjusted p value <0.05). Volcano plots showing the
DNA methylation changes versus the statistical signifi-
cance are presented in Fig. 3a, b. An overview of the
top-100 of differentially methylated positions with corre-
sponding p values and methylation changes is presented
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in Additional file 2: Table S1. Mean changes in DNA
methylation, as a result of the intervention, for these dif-
ferentially methylated positions ranged from −4 to 5 %
(Fig. 3e). Overall, positions within the CpG islands and
around the transcription start sites were overrepresented
among the positions that were differentially methylated
after the intervention with folic acid and vitamin B12
(Fig. 3c, d).
Differentially methylated positions that differ between
groups
Comparisons between the DNA methylation changes in
the participants receiving folic acid and vitamin B12
versus participants receiving the placebo showed one
differentially methylated position with a BH-adjusted
p value <0.05. This position (cg19380919) is located within
a non-CpG dense region (open sea) on chromosome 2. Fur-
ther exploration of the top-20 of differentially methylated
positions showed that most pronounced differences (>5 %)
were found for two probes on chromosome 4 and 1. For
one probe (cg01129246) within the body of GRXCR1, mean
DNA methylation increased with 2.6 % after the interven-
tion with folic acid and vitamin B12, whereas it decreased
with 4.1 % in the placebo group. Furthermore, DNA methy-
lation changes differed for cg06191076 within the promoter
region of the DIRAS3 gene (also known as ARHI), a
suggested tumor suppressor gene and member of the ras
superfamily (Table 2). For this position, mean DNA methy-
lation increased after intervention with folic acid and
vitamin B12 with 2.7 %, whereas it decreased with 2.5 % in
the placebo group (Fig. 3f). Stratification for MTHFR geno-
type did only reveal 2 and 3 (TT and CC, respectively) posi-
tions with differential methylation after the intervention
with folic acid and vitamin B12, indicating that the power
for stratified analyses may be insufficient as a consequence
of the limited sample sizes in the subgroups.
Differentially methylated regions that differ between
groups
Identification and characterization of differentially meth-
ylated regions (DMRs), consisting of multiple consecu-
tive positions, showed that 6 regions differed for the
participants receiving folic acid and vitamin B12 versus
placebo (BH-adjusted p value <0.05) (Table 3). Again,
for a DMR of 11 positions within DIRAS3 the most pro-
nounced difference (maximal 5.2 %) in DNA methyla-
tion changes was found (Table 3 and Fig. 4). For this
DMR, the mean percentage of DNA methylation in-
creased after intervention with folic acid and vitamin B12
(1.5 %), but decreased in the placebo group (−0.9 %). A
similar pattern was found for NODAL (nodal growth
differentiation factor) on chromosome 10, for which 2
consecutive positions located within the 3′ untranslated
region (3′UTR) were identified. After intervention with
folic acid and vitamin B12, the mean methylation for
these positions increased with 1.2 %, whereas in the
placebo group a modest decrease of −0.4 % was found.
Fig. 1 Flow diagram for the selection of participants and the analysis of samples. aSelf-reported change in use of dietary supplements containing
folic acid or vitamin B12.
bSerum levels of folate or vitamin B12 and plasma levels of homocysteine. Abbreviations: CRP C-reactive protein, MTHFR
methylenetetrahydrofolate reductase, SNP single nucleotide polymorphism, SWAN subset-quantile within array normalization
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Relation with serum or plasma levels of B-vitamins and
homocysteine
Changes in serum levels of folate or vitamin B12 and
plasma homocysteine after the 2-year intervention period
were fairly subjected to interindividual variation resulting
in an “overlap” between the intervention and placebo
group (Fig. 2). In addition to the comparisons for the DNA
methylation changes between these two groups, we there-
fore explored the relation between DNA methylation and
serum folate, vitamin B12 or plasma homocysteine levels in
a continuous manner. Applying the conservative threshold
for significance of BH-adjusted p values <0.05 revealed no
statistically significant positions related to folate levels. Ex-
ploration, however, of the top-35 positions for which DNA
methylation tends to be related to serum folate levels
showed a probe (cg24973150, p = 5.15E-05) located within
a CpG island in the promoter region (TSS200) of the
HOXB7 gene, which has been recently associated with the
risk of neural tube defects [31]. Most (32 of the top-35 po-
sitions) of the observed positions were positively related to
serum levels of folate, indicating that DNA methylation in-
creased with higher levels of serum folate. In addition to
the identification of individual positions, we subsequently
identified 173 DMRs that were related to folate levels. One
of the most prominent regions, consisting of 22 probes
and a mean BH-adjusted p value of 0.001, belongs to the
promoter region of HOXA4, another member of the
homeobox family. An overview of DNA methylation
changes in HOXB7, HOXA4, and the other HOX genes in
one of the four HOX gene clusters is presented in Fig. 5,
showing that mean DNA methylation for the majority of
these HOX genes tends to be increased after intervention
with folic acid and vitamin B12, whereas it mostly remained
stable or decreased in the placebo group.
Likewise, for plasma levels of homocysteine, 11 DMRs
were identified. As expected, an inverse association
between DNA methylation and plasma levels of homo-
cysteine was found for most (32 of the top-35 positions)
of the positions related to homocysteine levels. In com-
parison to folate and homocysteine, most pronounced
Table 1 Characteristics of the participants at baseline and after
2 years of intervention with either folic acid and vitamin B12 or
placebo
Folic acid and vitamin B12
(n = 44)
Placebo
(n = 43)
Baseline characteristics
Age at baseline
(years)
70.8 ± 2.9 71.1 ± 3.0
Women (%) 25 (57 %) 22 (51 %)
Body mass index
(kg/m2)
27.2 (24.4–29.7) 28.7 (25.7–31.2)
Smoking (%)a
Former 25 (57 %) 31 (72 %)
Never 19 (43 %) 12 (28 %)
MTHFR C677T
genotype (%)b
CC 22 (50 %) 20 (47 %)
TT 22 (50 %) 23 (54 %)
Biochemical analyses
Serum folate levels
(nmol/L)
Baseline 16.2 (13.1–24.4) 17.3 (14.1–21.5)
After intervention 52.3 (45.1–67.6) 23.1 (18.3–26.9)
Change 34.0 (26.5–47.6) 5.4 (2.0–9.6)
Serum vitamin B12 levels
(pmol/L)
Baseline 279 (232–358) 300 (204–365)
After intervention 595 (467–814) 325 (230–449)
Change 319 (197–462) 30.4 (−12.6–89.5)
Plasma homocysteine
levels (μmol/L)
Baseline 14.7 (13.1–16.3) 14.9 (13.1–16.3)
After intervention 9.6 (8.5–11.1) 13.7 (11.8–16.6)
Change −5.3 (−6.7 to −3.4) −1.5 (−2.4–0.6)
Data are presented as median (interquartile ranges) or numbers (%). aCurrent
smokers were not selected for the study population. bSingle nucleotide
polymorphism: rs1801133, participants with the CT genotype were not
selected for the current study
Fig. 2 Changes in serum levels of folate, vitamin B12, and plasma levels of homocysteine. Individual changes in serum levels of folate and vitamin
B12 and plasma levels of homocysteine after the 2-year intervention with folic acid and vitamin B12 or placebo. Horizontal lines represent
median ± interquartile ranges
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relations with DNA methylation were, however, found
for serum levels of vitamin B12. In total, 425 regions
were identified for which DNA methylation was related
to serum vitamin B12 levels (BH-adjusted p value <0.05).
An overview of the top-3 most statistically significant
positions related to folate, vitamin B12, or homocysteine
levels is presented in Fig. 6. A detailed list with differen-
tially methylated positions and regions related to either
folate, vitamin B12, or homocysteine levels is included in
Additional file 3: Table S2.
Discussion
The current study shows that long-term supplementa-
tion with folic acid and vitamin B12 resulted in DNA
methylation changes in leukocytes of older persons. We
identified several differentially methylated positions as
Fig. 3 Differentially methylated positions after the intervention with folic acid and vitamin B12. Volcano plots show the statistical significance
versus the changes in DNA methylation after the intervention with (a) the placebo or (b) folic acid and vitamin B12. Dashed lines represent 2 %
methylation changes and a p value of 1.0E-05. Features of the positions (n = 162) that were differentially methylated after the intervention with
folic acid and vitamin B12 are presented in (c) percentages of positions expressed per relationship to CpG islands for the differentially methylated
positions (n = 162) as well as for all considered positions on the Infinium HumanMethylation450 Beadchip (n = 431,312), and (d) percentage of
positions expressed per relationship to the nearest gene(s). e Number of positions according to the presented categories for absolute changes in
DNA methylation for the 162 positions that were differentially methylated after the intervention with folic acid and vitamin B12. f Individual
changes in DNA methylation for probe cg06191076 located within DIRAS3. Horizontal lines represent median ± interquartile ranges of DNA
methylation, which is expressed as a beta value (0–100 %). Abbreviations: TSS200 200 base pairs around the transcription start site, TSS1500 1500
base pairs around the transcription start site, 3′UTR 3′ untranslated region, 5′UTR 5′ untranslated region, IGR intergenic region
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well as regions for which the change in DNA methyla-
tion differed between the participants receiving folic acid
and vitamin B12 versus placebo. Furthermore, the DNA
methylation levels of several genomic loci were found to
correlate to serum levels of either folate, vitamin B12, or
plasma homocysteine. Most prominent DNA methylation
patterns associated with supplemental intake or status of
these B-vitamins seemed to be related to developmental
processes as well as carcinogenesis.
Based on comparisons between the two groups (folic
acid and vitamin B12 versus placebo), DIRAS3 was
identified as a gene of interest with a DMR consisting of
11 consecutive positions. DIRAS3, also known as ARHI,
is a maternally imprinted member of the ras superfamily
Table 2 The top-20 of differentially methylated positions representing changes in DNA methylation that differ between participants
receiving folic acid and vitamin B12 or placebo
Mean change in methylation (%)
CpG Chr Gene Gene feature p value Adjusted p value Folic acid and vitamin B12 Placebo
cg19380919 2 – – 9.9E-08 0.0426 1.0 −1.4
cg05308617 3 ARMC8 TSS200 8.4E-07 0.1810 0.6 −0.6
cg06016645 10 NODAL 3′UTR 1.6E-06 0.2323 1.5 −0.8
cg11567849 6 REV3L Body 2.7E-06 0.2495 0.8 −1.0
cg10367137 10 – – 3.8E-06 0.2495 0.7 −1.1
cg18514573 6 – – 4.0E-06 0.2495 0.6 −0.6
cg03330920 16 IFT140 Body 4.6E-06 0.2495 1.9 −2.1
cg01129246 4 GRXCR1 Body 4.9E-06 0.2495 2.6 −4.1
cg16895973 11 TOLLIP Body 6.0E-06 0.2495 1.3 −2.6
cg09708616 6 – – 6.3E-06 0.2495 1.4 −1.3
cg04530976 6 ZBTB9 Body 6.4E-06 0.2495 0.8 −0.9
cg27610561 20 SLC2A10 TSS1500 8.2E-06 0.2665 1.0 −1.6
cg05119686 10 – – 8.7E-06 0.2665 1.5 −1.1
cg03761210 20 NECAB3;C20orf144 Body 8.7E-06 0.2665 0.3 −0.3
cg07292606 2 TEX261 Body 9.4E-06 0.2665 2.0 −0.9
cg27194173 10 ADK Body 9.9E-06 0.2665 1.9 −0.9
cg06191076 1 DIRAS3 TSS200 1.3E-05 0.3192 2.7 −2.5
cg00066153 11 ACRV1 1stExon; 5′UTR 1.3E-05 0.3192 1.1 −0.9
cg20455570 7 OSBPL3 5′UTR 1.7E-05 0.3888 1.2 −1.0
cg24106824 17 MRPL12 3′UTR 2.0E-05 0.4105 1.1 −0.6
Mean changes in methylation are presented as beta-values ranging from 0–100 %. The adjusted p values for the comparisons between the two groups control
the false discovery rate using the Benjamini-Hochberg procedure. Abbreviations: Chr chromosome, TSS200 200 base pairs around the transcription start site,
TSS1500 1500 base pairs around the transcription start site, 3′UTR 3′ untranslated region, 5′UTR 5′ untranslated region
Table 3 Differentially methylated regions with DNA methylation changes that differ between participants receiving folic acid and
vitamin B12 or placebo
Gene Gene feature Chr hg19 coordinates Probes Minimal
p value
Mean
p value
Maximal difference in
methylation change (%)a
DIRAS3 5′UTR,1stExon,TSS200 1 68516080-68516627 11 0.0095 0.0175 5.2
– – 6 85478576-85478807 2 0.0155 0.0210 3.6
NODAL 3′UTR 10 72191686-72191804 2 0.0198 0.0231 2.3
ARMC8 TSS1500,TSS200 3 137905836-137906122 7 0.0361 0.0400 1.3
PRDM16 Body 1 3130485-3130550 3 0.0361 0.0361 2.8
GNA12 Body 7 2801424-2801732 3 0.0387 0.0437 −2.4
The DMRs were identified using the DMRcate package available through Bioconductor. The p values considered the false discovery rate and were adjusted using
the Benjamini-Hochberg procedure. The minimal and mean p value as well as the maximal difference in DNA methylation change were calculated based on the
indicated number of probes for each region. aThe maximal difference was calculated for the DNA methylation change after intervention with folic acid and
vitamin B12 versus placebo. Abbreviations: Chr chromosome, DMR differentially methylated region, h19 coordinates for the human genome based on the Genome
Reference Consortium Human Build 37 (hg19/GRCh37), TSS200 200 base pairs around the transcription start site, TSS1500 1500 base pairs around the transcription
start site, 3′UTR 3′ untranslated region, 5′UTR 5′ untranslated region
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and is considered to be a tumor suppressor gene [32].
Downregulation of DIRAS3 expression has been described
for several forms of cancer and has been specifically
associated with progression and invasive behavior of
neoplastic cells [33–35]. To what extent transcriptional
downregulation of DIRAS3 occurs via epigenetic mecha-
nisms is not exactly known, although previous work indi-
cated that regulation by miRNAs, chromatin remodeling
as well as promoter hypermethylation may be responsible
for this effect [35–37].
Fig. 4 The differentially methylated region within DIRAS3. Individual (dots) and median (lines) DNA methylation values for the positions within the
identified differentially methylated regions (DMRs) for DIRAS3 (chromosome 1) before (black) and after (red) the intervention with folic acid and vitamin B12
(n= 44) or placebo (n= 43). The DMRs were identified using the DMRcate package [81]. Coordinates for the human genome are based on h19/GRCh37
Fig. 5 The effect of folic acid and vitamin B12 on DNA methylation of HOX genes. Mean DNA methylation changes after a 2-year intervention
with folic acid and vitamin B12 (red, n = 44) or placebo (black, n = 43) for the 1052 positions located within one of the 39 HOX (homeobox) genes
located on cluster A (chromosome 7), cluster B (chromosome 17), cluster C (chromosome 12), or cluster D (chromosome 2). Only positions annotated
to one of these HOX genes were depicted; intergenic regions were not included in this figure. Bars are superimposed, meaning that red (folic acid and
vitamin B12) and black (placebo) bars are presented together, whenever applicable behind each other, and both reflect the actual values on the y-axis
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Another gene identified based on its DMR responsive
to the intervention with folic acid and vitamin B12 is the
nodal growth differentiation factor (NODAL), a member
of the transforming growth factor-β (TGF-beta) super-
family. Like DIRAS3, NODAL has been recognized for
its role in cancer progression, with abundant expression
of NODAL associated with cellular migration, invasion,
and metastatic behavior [38–41].
Noteworthy, NODAL is not only known for its role in
cancer progression as it has been originally identified as
a morphogen and regulator of mesoderm formation and
organization of axial structures during early-stage em-
bryogenesis [42, 43]. Upregulation of NODAL expression
as a consequence of tobacco or nicotine exposure in
differentiating human embryonic stem cells (hESCs)
suggests that the NODAL signaling routes are vulnerable
to environmental exposures or stimuli during embryonic
development [44]. Interestingly, it has been recently
demonstrated that expression of NODAL is regulated via
an epigenetic regulatory element for which dynamic
changes in DNA methylation were described throughout
embryonic development [45]. Although this epigenetic
regulatory element was found upstream of the NODAL
gene, whereas our small DMR was located in the 3′UTR,
these results support our findings that NODAL may be
sensitive to endogenous or environmental exposures.
Besides NODAL, also positions or regions within other
developmental genes have been identified as potentially
responsive to the intervention with folic acid and
vitamin B12 or were related to serum folate levels in our
study. The homeobox B7 (HOXB7) gene was identified
for its relation with serum folate levels of the partici-
pants in the current study. HOXB7 is a member of the
homeobox family [46] and occurs in a cluster with other
A
B
C
Fig. 6 The relation between serum levels of folate, vitamin B12 and plasma homocysteine and DNA methylation. The top-3 of the positions (based
on lowest p values derived from the limma regression analyses) related to a serum folate levels, b serum vitamin B12 levels, and c plasma homocysteine
levels. Linear regression lines are presented in blue and the Pearson correlation coefficient (r) is presented. P values refer to non-adjusted p values from the
limma regression analyses. All samples (n= 174) were included in the analyses, except for plasma homocysteine for which two samples were excluded
because of missing values
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homeobox B genes. For HOXA4, a DMR was related to
serum folate levels. The highly conserved HOX genes
are considered important transcriptional regulators
during embryonic development, where they are mainly
responsible for vertebral axial patterning [47, 48].
Epigenetic control of HOX genes in developmental
processes related to health and disease has been de-
scribed previously [47, 49]. Hypomethylation of HOXB7
has been recently recognized as a risk factor for neural
tube defects in a case-control study [31]. It is firmly
established that periconceptional folic acid supplementation
decreases the risk of neural tube defects in the offspring
[50, 51]. To what extent HOX or other developmental
genes are key targets for the prevention of neural tube
defects through folic acid supplementation has not been
described extensively so far [52]. The clinical relevance of
our findings with respect to mechanisms underlying pre-
vention of neural tube defects, however, is questionable
since we found modest increases (~2–5 %) in DNA methy-
lation of the NODAL or HOX genes after supplementation
in our elderly population. Case-control studies have previ-
ously shown that DNA methylation of several HOX genes
differed up to 29 % between children with myelomeningo-
cele (a form of spina bidifa) and healthy controls [31]. To
what extent epigenetic control of developmental genes dur-
ing fetal development [1] can be translated into an aging
population, and vice versa, is not clear. Thus, our careful
and explorative hypotheses about the effects of folic acid
and vitamin B12 on epigenetic processes in relation to pro-
gramming of (early) developmental genes warrant further
investigation and confirmation in future research with a
specific focus on the suggested interaction between genetic,
biological, and nutritional factors [53].
As stated before, aberrant DNA methylation or expres-
sion of several HOX genes, NODAL and DIRAS3 have
been implicated in the etiology of cancer [54, 55].
Members of the homeobox family as well as NODAL are
specifically associated with cancer progression and
metastatic behavior [56–59]. Reactivation of embryonic
pathways in cancer cells may contribute to uncontrolled
differentiation, proliferation, invasion, and metastatic be-
havior. To what extent the suggested increases in DNA
methylation of tumor-related genes such as DIRAS3,
NODAL, HOXB7, HOXA4, and other HOX genes may
contribute to the pathogenesis of cancer cannot be con-
cluded from the current study. Theoretically, our findings,
however, support the hypothesis that folic acid and
possibly other B-vitamins specifically increase cancer risk
if preclinical neoplastic lesions already exist, pointing
toward an effect on progression rather than development
of cancer [27, 29]. Our findings may also explain the
explorative results of the entire B-vitamins for the
PRevention Of Osteoporotic Fractures (B-PROOF) study,
where a slightly increased cancer risk was reported after
intervention with folic acid and vitamin B12 as compared
to the placebo group (hazard ration 1.56; 95 % confidence
interval 1.04-2.30) [60]. Taken altogether, our data suggest
that supplementation with folic acid and vitamin B12, and
consequential changes in serum levels of the correspond-
ing B-vitamins or plasma homocysteine, in older subjects
is associated with changes in DNA methylation of several
genes implicated in normal developmental processes,
which may be reactivated or deregulated during carcino-
genesis. It should be noted that the observed effects on
DNA methylation were marginal and that biological and
functional consequences with respect to gene expression
cannot be validated with the current study. On the other
hand, previous studies from our groups and others have
already shown that nutritional or environmental exposures
often result in small, but biologically meaningful, effects on
DNA methylation in comparison to the tremendously
deviating methylation patterns observed in complex
diseases such as cancer [61–63].
Potential limitations of our study include the relatively
heterogeneous study population with respect to charac-
teristics that may have occurred or changed during the
intervention period, such as changes in dietary habits,
use of drugs, and presentation of diseases. It should be
noted, however, that these characteristics represent and
reflect the general elderly population, which is therefore
an advantage with respect to the generalizability of our
findings. For disease-related findings, it is questionable
whether our results observed in leukocytes also reflect
the situation in the tissue of interest, since DNA methy-
lation patterns are highly tissue specific [64–66]. Finally,
all participants in our study received 15 μg of vitamin
D3 per day in order to ensure a normal vitamin D status.
Therefore, we cannot exclude the possibility that some
DNA methylation changes may be predominantly attrib-
utable to vitamin D rather than folic acid and vitamin
B12 [67]. However, since all participants, both from the
intervention group and the placebo group, received vita-
min D in their study tablets (also containing the placebo
or folic acid/vitamin B12), this did not hinder our main
analyses dedicated to comparisons between these two
groups. Although, the results from our study were fairly
consistent with other studies and current insights, strict
replication of our findings was not feasible so far
given the unique design of our long-term intervention
study with folic acid as well as vitamin B12 among
elderly subjects.
Strengths of our study include the analyses of genome-
wide DNA methylation both before and after long-term
supplementation, which allow comparisons within indi-
viduals over time. Furthermore, our population consisted
of older subjects with mildly elevated homocysteine
levels. Elevated homocysteine levels, which are com-
mon among elderly subjects in The Netherlands [68],
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may point toward inadequate levels or deficiencies of
folate and vitamin B12 [69]. Therefore, especially, this
population may have benefited from the prolonged
supplementation with these B-vitamins and thus enabled
detection of changes in DNA methylation patterns.
Conclusions
Long-term supplementation with folic acid and vitamin
B12 in elderly subjects with mildly elevated homocysteine
levels resulted in changes in DNA methylation of several
genes implicated in normal developmental processes and
carcinogenesis. These findings may provide unique leads
for further research unraveling the mechanisms under-
lying the effects of B-vitamins on health and disease
during the life cycle.
Methods
Design and recruitment
The current study was part of a double-blind, randomized,
and placebo-controlled trial on the effects of supplemental
intake of folic acid and vitamin B12 on fracture incidence
(B-PROOF) in The Netherlands [60, 70]. Design of the
B-PROOF study and recruitment of the participants
have been described in detail previously [70]. Briefly, men
and women, aged 65 years and older, with an elevated
homocysteine level (12–50 μmol/L) were eligible to par-
ticipate in this study. Between September 2008 and March
2011, over 69,000 subjects were screened and 2919 partic-
ipants were finally enrolled in the B-PROOF study (Fig. 1).
All participants provided written informed consent and
the study protocol was approved by the institutional
Medical Ethics Committee. Participants were randomly
assigned to take 400 μg folic acid and 500 μg vitamin B12
(Orthica, Almere, The Netherlands) per day or a placebo
(Orthica, Almere, The Netherlands) during an intervention
period of 2 years. Moreover, all participants received a daily
dose of 15 μg vitamin D3, in the same tablet as the placebo
or B-vitamins, to ensure a normal vitamin D status.
For the current study, a subgroup of participants was
selected from the B-PROOF study cohort. From the 331
participants, who were among the first who completed
the intervention period of 2 years, 92 participants were
selected for DNA methylation analyses. In order to
obtain a relatively homogenous study population, our
predefined selection criteria included: age between 65
and 75 years and no reported changes in use of dietary
supplements containing folic acid or vitamin B12 during
the study. Levels of the C-reactive protein (CRP) at base-
line should be ≤10 mg/L, because elevated levels of CRP
as a consequence of inflammation may indicate aberrant
leukocyte counts. Furthermore, participants who were
current smokers, or excessive alcohol users (at least once
a week ≥6 glasses of alcohol or 5–7 days/week ≥4 glasses
of alcohol) [71] at baseline were not selected for the
current study. All participants had elevated homocyst-
eine levels, which is in line with inclusion criteria of the
B-PROOF study. Given the essential role of MTHFR in
folate-mediated one-carbon metabolism, the functional
C677T single nucleotide polymorphism (SNP) of the
MTHFR gene was considered as well for the selection
procedure. Participants with the MTHFR (C677T) CC
(n = 46) and TT (n = 46) genotypes were equally and ex-
clusively represented in the current study. The MTHFR
SNP was determined using the Illumina Omni-express
array (Illumina Inc., San Diego, CA, USA).
Sample collection and biochemical analyses
At baseline and after 2 years of intervention, blood sam-
ples were collected from all 92 participants. Serum levels
of folate and vitamin B12 were determined using electro-
chemiluminescence immunoassays (Elecsys 2010, Roche,
Almere, The Netherlands). Depending on the study
center, plasma levels of homocysteine were measured
using the Architect i2000 RS analyzer (VU University
Medical Center, Amsterdam), HPLC (Wageningen Uni-
versity, Wageningen), or LC-MS/MS method (Erasmus
MC, Rotterdam). According to a cross-calibration, out-
comes of the three centers did not differ significantly [60].
Genome-wide DNA methylation analysis
DNA was isolated from buffy coats and 500 ng genomic
DNA was bisulfite converted using the EZ DNA Methy-
lation Kit according to the manufacturer instructions
(Zymo Research, Freiburg, Germany). Bisulfite converted
DNA was used for the genome-wide DNA methylation
analyses. Genome-wide DNA methylation was deter-
mined in a total of 184 samples from 92 participants
using the Infinium HumanMethylation450 BeadChip
(Illumina). All samples were processed and analyzed at the
Genetic laboratory of Internal Medicine of the Erasmus
MC, Rotterdam, The Netherlands. Initial quality control
of the samples revealed that one participant had to be ex-
cluded because bisulfite conversion for the baseline sam-
ple failed. Furthermore, two participants were excluded
since their baseline samples showed (1) an average inten-
sity signal in the methylated or unmethylated channel
below our predefined threshold of 1966 and (2) a percent-
age of probes with a call rate <97.5 %. Clustering based on
the 65 known SNP probes on the BeadChip as well as
multidimensional scaling stratified for gender, revealed
two potential sample mix-ups. The corresponding partici-
pants of these samples were excluded resulting in samples
from 87 participants available for final analysis (Fig. 1).
Raw idat.files were subsequently used for analysis in
the R statistical environment (R 3.1.2) through the minfi
package (version 1.12.0) available from Bioconductor [72].
Preprocessing of the data included filtering of 65 control
probes containing known SNPs and probes annotated to
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the X and Y chromosome. Probes with a detection p value
of >0.01 in at least one sample were filtered, as these
probes did not surpass the background signal. Finally,
probes containing an SNP (based on the dbSNP version
137) [73] at the CpG interrogation and/or the single
nucleotide extension were excluded, resulting in 431,312
probes included in the analyses (Fig. 1).
Filtered data were normalized using the SWAN
normalization procedure [74] available through the minfi
package [72]. The datasets were annotated based on the
ilmn12.hg19 annotation [75]. The M-values, which are
the log2 ratios of the methylated versus the unmethy-
lated probe intensities, were used for statistical testing as
recommended by Du et al. [76]. For visualization
purposes, methylation status of the individual probes
was expressed as a β-value. These β-values range from 0
or 0 % (fully unmethylated) to 1 or 100 % (fully methyl-
ated). Phenotypic data and idat-files from the genome-
wide DNA methylation analysis are available through
the NCBI’s Gene Expression Omnibus (GEO) repository
[77] with accession number GSE74548.
Differentially methylated positions
Initially, differentially methylated positions, representing
changes in DNA methylation over time, were identified
in both the placebo as well as the intervention group
using a multi-level linear regression analysis within the
limma package [78, 79]. For these analyses, subjects were
treated as random effects using the “duplicateCorrelation”
function in order to conduct the comparisons in a
pairwise manner [78, 80].
Differences in changes in DNA methylation between
the placebo and intervention group were identified
using this multi-level linear regression analysis as well
[78, 80]. The contrast ((Placebo_followup-Placebo_baseline)-
(Intervention_followup-Intervention_baseline)) allowed
the comparison between DNA methylation changes in the
two groups.
Besides the comparisons between the two groups,
differentially methylated positions were identified as a func-
tion of serum folate, vitamin B12, or plasma homocysteine
levels using the dmpFinder function for continuous pheno-
types (available from the minfi package [72]). For these
analyses, log10-transformed serum levels of folate, vitamin
B12 levels, or plasma homocysteine at baseline and after
intervention were considered as continuous variables in
the linear regression analyses (n = 174).
Differentially methylated regions
Identification of differentially methylated regions (DMRs)
was conducted using the DMRcate package available
through Bioconductor [81]. DMRs were defined as regions
with a maximal distance of 1000 nucleotides between
consecutive probes [81]. Identified DMRs consisting of a
single probe were excluded for further analyses. Unless
otherwise stated, we have taken into account the issue of
multiple testing for all analyses by considering p values
which are adjusted for the false discovery rate (FDR) by
using the Benjamini-Hochberg (BH) procedure [82].
Statistical considerations
Samples with a heterogeneous cell population are a major
issue for epigenomic analyses, since DNA methylation
shows a pronounced cell-type specific pattern [65]. In order
to determine whether the leukocyte fractions differed
between the groups or baseline and follow-up samples, we
predicted the leukocyte composition using the Houseman
method [83, 84] implemented in minfi [72]. For a subgroup
of participants (n = 85, follow-up samples only), automated
cell counts (lymphocytes, monocytes and basophil, eosino-
phil and neutrophil granulocytes) were available. Pearson
correlation coefficients were calculated for the predicted
and measured counts of these specific leukocyte fractions.
The statistical analyses were adjusted for the different
cell fractions by inclusion of predicted percentages of
CD4+ and CD8+ T-lymphocytes, B-lymphocytes, natural
killer cells, monocytes, and granulocytes as covariates in
the linear regression models. Also, the plates used for
the bisulfite conversion (four in total) were included as
covariates in the models.
Since numerous demographic and biochemical variables
were not normally distributed, these data were summarized
as median and interquartile ranges (IQR) or numbers and
percentages. The Mann-Whitney U test was used to com-
pare characteristics and changes in serum levels of folate,
vitamin B12, or plasma homocysteine between the interven-
tion group and the placebo group. The Statistical package
for Social Sciences (SPSS version 22) was, unless otherwise
stated, used for all the statistical analyses regarding the
descriptive and biochemical parameters.
Additional files
Additional file 1: Figure S1. The mean proportion of the leukocyte
fractions in the buffy coat samples collected before and after intervention
with folic acid and vitamin B12 (n=44) or placebo (n=43). Estimates of
the leukocyte fractions were based on the Houseman method.
Additional file 2: Table S1. Top-100 positions that are differentially
methylated after intervention with folic acid and vitamin B12.
Overview of the top-100 positions that are differentially methylated
(Benjamini-Hochberg adjusted p-value <0.05) after intervention with
folic acid and vitamin B12 (FA/vB12). Changes for DNA methylation
in the intervention group as well as the placebo group are presented
as % beta-values and can range from 0-100 %.
Additional file 3: Table S2a and S2b. Differentially methylated
positions and regions related to serum levels of folate, vitamin B12
of plasma homocysteine. Overview of the top-10 of a) differentially
methylated positions as well as b) regions related to serum levels of
folate, vitamin B12 of plasma homocysteine.
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